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Background: Hepatocellular carcinoma (HCC) is one of the most common malignancies and a major cause of
cancer-related mortality in the world. MicroRNAs (miRNAs) are small, noncoding RNAs that play essential roles in
various stages during cancer progression. The aim of the current study was to elucidate the role of miR-1269 in the
pathogenesis of HCC.
Methods: The expression of miR-1269 in HCC cells and tissues were determined by Real-time PCR analysis. Cell
viability, colony formation and anchorage-independent growth ability assays were performed to examine cell
proliferative capacity and tumorigenicity. Flow cytometry analysis was conducted to determine cell cycle progression.
The expression of p21, CyclinD1, phosphorylated Rb, Rb and FOXO1 were examined by Western blotting analysis.
Luciferase assay was used to determine whether FOXO1 is the direct target of miR-1269.
Results: miR-1269 was upregulated in HCC cells and tissues. Ectopic miR-1269 expression promoted, but inhibition of
miR-1269 reduced, proliferation, tumorigenicity and cell cycle progression of HCC cells. Furthermore, we demonstrated
that FOXO1 was a direct target of miR-1269. Suppression of FOXO1 by miR-1269 was associated with dysregulation of
p21, cyclin D1, phosphorylated Rb and Ki67 expression, thereby playing an essential role in the growth of HCC cells.
Conclusions: Our study indicated that overexpression of miR-1269 promotes cell proliferation in HCC through directly
suppressing FOXO1, and functions as an oncomiR in HCC.
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Hepatocellular carcinoma (HCC) is one of the most com-
mon cancers in the world, and the third most common
cause of cancer-related death, especially in Asian countries
[1,2]. HCC is particularly problematic in China, where the
incidence of HCC is much higher than that in other Asian
countries [2]. Most patients with HCC are asymptomatic
until the later stages of disease, and the lack of an effective
way of diagnosis at an earlier stage means the these
patients have a poor prognosis [3]. The identification of
specific and effective diagnostic biomarkers for HCC is of* Correspondence: drxueping@medmail.com.cn
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unless otherwise stated.critical importance. Therefore, studies into the biology of
HCC initiation and progression are also urgently needed
to develop effective therapeutic strategies.
MicroRNAs (miRNAs) are a class of newly recognized
small noncoding RNAs, which have been demonstrated to
be as important factors in multiple biological processes
[4-7]. It has been shown that miRNAs negatively regulate
gene expression levels post-transcriptionally through tar-
geting the 3’-untranslated region (3’-UTR) of mRNAs in a
sequence-specific manner [8,9]. An increasing number of
studies have shown that miRNAs play essential roles in
the biology of various human cancers through regulation
of multiple biological process, such as cell growth and
differentiation, apoptosis, metastasis and angiogenesis
[6,10,11]. Based on the critical role of miRNAs in car-
cinogenesis and cancer progression, miRNAs have beend. This is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/4.0), which permits unrestricted use, distribution, and
iginal work is properly credited. The Creative Commons Public Domain
g/publicdomain/zero/1.0/) applies to the data made available in this article,
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therapy.
The regulation of miRNAs during HCC progression has
been arousing increasing attentions recently. Alexander H.
et al. reported that the pan-deacetylase inhibitor panobi-
nostat suppresses the expression of oncogenic miRNAs in
HCC cell lines and anobinostat exerts its anti-cancer effect
by suppressing these miRNAs and restoring the expres-
sion of their corresponding tumor suppressor targets
[12]. Panobinostat strongly downregulated High Mobil-
ity Group AT-2 hook (HMGA2), a nuclear non-histone
transcriptional co-factor with known oncogenic proper-
ties, in HepG2 and Hep3B cells and the effect was
found to be mediated by transcriptional upregulation
and promotion of the maturation of the tumor suppres-
sor miRNA hsa-let-7b, which could inhibit HMGA2 ex-
pression via RNA interference pathways [13]. However,
the network regulation of miRNAs in HCC progression
has not been elucidated clearly.
In the current study, we found that miR-1269 was upreg-
ulated through analysis of a published micro-array-based
high-throughput assessment (NCBI/GEO/GSE36915), and
further confirmed this result in HCC tissue and cell lines.
Ectopic overexpression of miR-1269 in HCC cell lines led
to the promotion of cell growth rate, tumorigenicity and
cell cycle progression. Furthermore, we demonstrated that
the tumor suppressor gene FOXO1 is a direct target of
miR-1269. In conclusion, our results indicated that overex-
pression of miR-1269 could promote cell proliferation,




Immortalized normal liver epithelial cell, THLE3, was
purchased from the American Type Culture Collection
(ATCC, Manassas, VA, USA). The HCC cell lines (Hep3B,
HepG2, BEL-7402, BEL-7404, SNU-398, SNU-449, Huh7,
and QGY-7703), were purchased from the ATCC, were
maintained in Dulbecco’s modified Eagle’s medium
(Invitrogen, Carlsbad, CA) supplemented with 10% fetal
bovine serum (Invitrogen), 100 U/ml penicillin and 100 μg/ml
streptomycin (Invitrogen), within a humidified atmos-
phere containing 5% CO2 at 37°C. Normal hepatocytes
s established from fresh specimens of normal hepatic
tissue, which had been histopathologically diagnosed
and verified by experienced pathologists.
Tissue specimens
A total 23 pairs of HCC tumors and matched normal
tissue from adjacent regions, which were diagnosed
histopathologically by experienced pathologists, were
used in this study. Fresh HCC tissues and normal hep-
atic tissues were collected from patients undergoingcurative resection and diagnosed histopathologically at
the department of hepatobiliary surgery in the Second
Affiliated Hospital of Guangzhou Medical University. All
samples were immediately frozen and stored in liquid ni-
trogen before further analysis. All samples were obtained
with informed consent and this study was approved by
of Sun Yat-sen University Cancer Center Institutional
Review Board.
Plasmid, siRNA and generation of stably engineered cell
lines
The miR-1269 expression plasmid was generated by
cloning the genomic pre-miR-1269 gene into the retro-
viral transfer plasmid pMSCV-puro (Clontech Labora-
tories, Mountain View, CA, USA). The miR-1269 mimic,
miR-1269 mutant mimic (miR-1269-mut), miR-1269 in-
hibitor , negative control (NC) and FOXO1 siRNA were
purchased from RiboBio (RiboBio, Guangzhou, Guangdong,
China). Transfection of oligonucleotides and siRNA were
performed using Lipofectamine 2000 reagent (Invitrogen,
Carlsbad, CA, USA), according to the manufacturer’s
instructions. The stably engineered pMSCV-miR-1269
cell line was established using standard methods [14].
Briefly, pMSCV-miR-1269 was cotransfected with the
packaging plasmid into 293FT cells. Cell supernatants
were then collected after 36 h and incubated with HCC
cell lines for 24 h in the presence of polybrene (2.5 μg/ml;
Sigma, Saint Louis, MO, USA). Puromycin (1.5 μg/ml;
Sigma) was used to select stably transduced cells over a
10 day time period, according to the manufacturer’s
instructions.
RNA isolation and quantitative reverse-transcription PCR
(qRT-PCR)
Total cellular RNA was extracted using Trizol reagent
(Invitrogen), according to the manufacturer’s protocol.
SYBR Green I (Molecular Probes, Invitrogen) was used
to quantify PCR amplification and the qRT-PCR was
performed and analyzed using a 7500 Fast Real-Time
Sequence detection system (Applied Biosystems, Foster
City, CA, USA). miRNA quantification was determined
by using Bulge-loop™ miRNA qRT-PCR Primer Set
(one RT primer and a pair of qPCR primers for each
set) specific for miR-1269, designed by RiboBio. The
relative expression levels of the miRNA were calculated
as 2-[(Ct of miRNA) – (Ct of U6)] after normalization with
reference to the expression of small nuclear RNA U6.
The primers used for stem-loop reverse-transcription
PCR for miR-1269 and U6 were purchased from RiboBio.
Expression levels of genes were normalized to that of the
housekeeping gene GAPDH as the control and calculated
as 2-[(Ct of GENES) – (Ct of GAPDH)]). The following primers
were used: p21 forward, 5’-CATGGGTTCTGACGGAC
AT-3’, p21 reverse, 5’-AGTCAGTTCCTTGTGGAG CC-3’;
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A-3’, Cyclin D1 forward, 5’-AACTACCTGGACCGCTT
CCT-3’, and Cyclin D1 reverse, 5’-CCACTTGAGCTT
GTT CACCA-3’.
Western blotting
Total protein was extracted from whole cells and 20 μg of
isolated protein was separated by SDS-PAGE and electro-
blotted onto a PVDF membrane (Bio-Rad Laboratories,
Hercules, CA, USA). The membranes were then probed
with antibodies against FOXO1, p21, CyclinD1, phosphor-
ylated Rb, Rb, and α-Tubulin (Cell Signaling, Danvers,
MA, USA), using standard protocols.
Cell viability assay
Cells were seeded onto 96-well plates (2 × 103 cells per well),
and 100 μl 3-(4, 5-Dimethyl-2-thiazolyl)-2, 5-diphenyl-2H-
tetrazolium bromide (MTT, 0.5 mg/ml, Sigma) was
added at the indicated time points and incubated for 4
h at 37°C. DMSO (150 μl) was then added after removal
of the culture medium (Sigma), and the absorbance was
measured at 570 nm, with 655 nm as the reference
wavelength.
Colony formation assay
Cells were seeded into 6-cm tissue culture dishes (0.5 ×
103 cells per well) and cultured for 14 days. Cells were
then fixed with 10% formaldehyde for 15 min and subse-
quently stained with 1.0% crystal violet for 5 min. The
number of colonies formed was counted in 10 different
fields.
Anchorage-independent growth ability assay
Cells (1× 103) were trypsinized and suspended in 2 ml of
complete medium plus 0.33% agar (Invitrogen), and
plated in 6-cm culture dishes on top of a bottom agar
layer (0.66% complete medium agar), and incubated at
37°C for 2 weeks. Colonies greater than 0.1 mm in diam-
eter were counted.
Flow cytometry
Cells were harvested by trypsinization, washed in ice-
cold PBS, and fixed in 75% ice-cold ethanol. Cells were
then treated with Bovine pancreatic RNAase (2 μg/ml;
Sigma) at 37°C for 30 min, followed by incubation with
propidium iodide (20 μg/ml; Sigma) for 20 min. Cell
cycle analysis was determined using a BD LSRII Flow
Cytometry System with FACSDiva software (BD Bioscience,
Franklin Lakes, USA).
Luciferase assay
A region of the human FOXO1 3’-UTR containing
three miR-1269 binding sites was amplified by PCR and
cloned into vector pGL3 (Promega, Madison, WI, USA).Cells were seeded in triplicate in 24-well plate and allowed
to settle for 24 h. One hundred nanograms of pGL3-
FOXO1-luciferase plasmid were transfected into HCC
cells using the Lipofectamine 2000 reagent. Luciferase and
control signals were measured at 48 h after transfection
using the Dual Luciferase Reporter Assay Kit (Promega),
according to the protocol provided by the manufacturer.
Statistical analysis
Student’s t-test was used to evaluate the significant dif-
ference between two groups of data in all the pertinent
experiments. All data were expressed as the mean ±
standard deviation (SD) for three independent experi-
ments. Results were considered statistically significant
when a P-value < 0.05 was obtained.
Results
MiR-1269 is upregulated in HCC tissues and cells
By analyzing a published micro-array-based high-throughput
assessment (NCBI/GEO/GSE36915; n (Non-tumor) = 21;
n (Tumor) =68), miR-1269 was found to be significantly
upregulated in HCC tissues, compared with that in non-
tumor tissues (P < 0.05; Figure 1A). We further examined
the expression level of miR-1269 in HCC tissues and cell
lines by qRT-PCR. As shown in Figure 1B, miR-1269 was
upregulated in all 23 pairs of HCC tissue, compared with
the adjacent noncancerous hepatic tissues. Moreover, we
found that miR-1269 was also upregulated in eight
HCC cell lines (Hep3B, HepG2, BEL-7402, BEL-7404,
MHCC97H, MHCC97L, Huh7, and QGY-7703), com-
pared with that in the normal liver epithelial cell line
THLE3 cells and normal hepatocytes (Normal) (Figure 1C).
Taken together, these data demonstrate that miR-1269
expression is elevated in HCC tissues and cell lines.
Ectopic overexpression of miR-1269 promotes proliferation
of HCC cells
To explore the biological function of miR-1269 in HCC
progression, BEL-7404 and Huh7 cells stably overex-
pressing miR-1269 were established (Figure 2A). Cell
viability was then measured by MTT assay. A shown in
Figure 2B, ectopic expression of miR-1269 increased the
growth rate of both HCC cell lines. Colony formation
assay showed that upregulation of miR-1269 promoted
the colony formation capacity of BEL-7404 and Huh7
cells (Figure 2C). Consistently, anchorage-independent
growth assay revealed that the cells stably expressing
miR-1269 formed more and larger-sized colonies than
the control cells (Figure 2D). Furthermore, cell cycle
analysis by flow cytometry showed a dramatic decrease
in the percentage of cells in the G1/G0 phase and an in-
crease in the percentage of cells in the S phase in miR-
1269-overexpressing cells (Figure 2E). Collectively, these
results suggest that upregulation of miR-1269 enhanced
Figure 1 MiR-1269 is upregulated in HCC. A. miR-1269 is upregulated in HCC tissues compared with normal liver tissue (P = 0.015; NCBI/GEO/
GSE36915). B. Real-time PCR analysis of miR-1269 expression in 23 paired cancerous tissues (T) and their adjacent noncancerous hepatic tissues
(ANT). Transcript levels were normalized to U6 expression. C. Real-time PCR analysis of miR-1269 expression in several HCC cell lines compared to
normal hepatic cells as control. Transcript levels were normalized to U6 expression. Each bar represents the mean ± SD of three independent
experiments. * P < 0.05.
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sion of HCC cells.
Inhibition of miR-1269 suppresses proliferation of HCC
cells
To further explore the role of miR-1269 in promoting
HCC cell proliferation, loss of function approach using a
miR-1269 inhibitor were performed (Figure 3A). Ana-
lysis by MTT assay showed that downregulation of miR-
1269 markedly decreased the growth rate of BEL-7404
and Huh7 HCC cells transfected with the miR-1269 in-
hibitor, compared with that of control cells (Figure 3B).
The colony formation and anchorage-independent growth
assays both revealed that HCC cells transfected with the
miR-1269 inhibitor produced fewer and smaller colonies
than the NC cells (Figure 3C and D). Moreover, the result
of flow cytometry showed an obvious increase in the per-
centage of cells in the G1/G0 phase and a decrease in the
percentage of cells in the S phase in miR-1269 inhibited
cells, compared with control cells (Figure 3E). Taken to-
gether, these results suggest that inhibition of miR-1269
suppresses the proliferation, tumorigenicity and cell cycle
progression of HCC cells.
FOXO1 is a direct target of miR-1269 in HCC cells
It is known that miRNAs function by negatively regulat-
ing mRNAs via targeting their 3’UTRs. Thus, we usedpublicly available algorithms (TargetScan 6.2) to predict
the potential targets of miR-1269. As shown in Figure 4A,
there are three miR-1269 binding sites in the FOXO1
mRNA 3’UTR, including one conserved and two poorly
conserved binding sites. Importantly, western blotting
analysis showed that FOXO1 expression was downregu-
lated in the eight pairs of HCC tissue, compared with the
adjacent noncancerous hepatic tissues, and statistical ana-
lysis revealed that miR-1269 levels inversely correlated
with the expression of FOXO1 in the clinical HCC sam-
ples (Figure 4B), suggesting that miR-1269 might play role
in regulation of FOXO1 in HCC. Indeed, FOXO1 expres-
sion was found to be downregulated in the miR-1269-
overexpressing BEL-7404 and Huh7 cells but upregulated
in the cells transfected with miR-1269 inhibitor. In
addition, overexpressing miR-1269 decreased the expres-
sion of p-FOXO1, but we did not found significant alter-
ations of FOXO1 in miR-1269-inhibited cells (Figure 4C).
To further confirm the direct regulation of FOXO1 by
miR-1269, the pGL3-FOXO1-3’-UTR-luciferase reporter,
containing the three putative miR-1269 binding sites,
was constructed. The luciferase assay results showed
that ectopic overexpression of miR-1269 decreased, but
inhibition of miR-1269, increased luciferase activity of
the pGL3-FOXO1-3’-UTR reporter (Figure 4D). Mean-
while, mutant miR-1269 failed to show an inhibitory effect
on luciferase expression driven by the pGL3-FOXO1 -3’-
Figure 2 MiR-1269 enhances the proliferation and tumorigenicity of HCC cells. A. Real-time PCR analysis of miR-1269 in BEL-7404 and Huh7
cells stably overexpressing miR-1269. Transcript levels were normalized to U6 expression. B. The effects of miR-1269 overexpression on cell viability
of the indicated cell lines analyzed by MTT assay. C. Representative micrographs (left panel) and quantification (right panel) of crystal violet stained
colonies formed by the indicated cell lines. D. Representative micrographs (left panel) and quantification (right panel) of cell colonies determined by
anchorage-independent growth ability assay. E. The effect of miR-1269 on cell cycle progression of the indicated cell lines analyzed by flow cytometry.
Each bar represents the mean ± SD of three independent experiments. * P < 0.05.
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results suggest that miR-1269 directly targets FOXO1 in
HCC cells.
Given that our results indicated miR-1269 could influ-
ence HCC cell proliferation, we investigated its effects on
the expression level of FOXO1 downstream genes, such
as p21Cip1, cyclin D1, and Rb. As shown in Figure 4E and
F, p21Cip1 was downregulated, but cyclin D1 and phos-
phorylated Rb, were upregulated in miR-1269-transfected
cells. As expected, p21Cip1 was upregulated, whereas cyc-
lin D1 and phosphorylated Rb were downregulated, inmiR-1269-inhibitor transfected cells (Figure 4E and F).
These results suggest that miR-1269 plays an important
role in the proliferation of HCC cells via regulation of
FOXO1.
Suppression of FOXO1 is essential for miR-1269-induced
cell proliferation in HCC
To further confirm the effect of FOXO1 suppression on
miR-1269-mediated proliferation of HCC cells, siRNA
assay was used to suppress endogenous FOXO1 expres-
sion (Figure 5A). Analysis by MTT assay indicated that
Figure 3 Inhibition of miR-1269 suppresses the proliferation and tumorigenicity of HCC cells. A. Real-time PCR analysis miR-1269 in
BEL-7404 and Huh7 cells transfected with a miR-1269 inhibitor. Transcript levels were normalized to U6 expression. B. The effects of miR-1269
inhibition on cell viability of the indicated cell lines analyzed by MTT assay. C. Representative micrographs (left panel) and quantification (right
panel) of crystal violet stained colonies formed by the indicated cell lines. D. Effects of miR-1269 inhibition on the tumorigenicity of the indicated
cell lines determined by anchorage-independent growth ability assay. E. The effect of miR-1269 on cell cycle progression of the indicated cell
lines analyzed by flow cytometry. Each bar represents the mean ± SD of three independent experiments. * P < 0.05.
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miR-1269 inhibitor increased the growth rate of HCC
cells (Figure 5B). The colony formation and anchorage-
independent growth assays both showed that silencing
FOXO1 expression could reverse the inhibitory effect
of the miR-1269 inhibitor on HCC cell proliferation
(Figure 5C and D). These results further confirm that miR-
1269 enhances HCC cell proliferation and tumorigenicity
by downregulation of FOXO1 expression, and that FOXO1
suppression is essential for miR-1269-mediated effects on
HCC cell proliferation and tumorigenicity.Discussion
The key finding of the current study is that miR-1296 is
significantly upregulated in HCC cells and tissues, com-
pared with normal hepatocytes and liver tissues. Further-
more, we found that ectopic overexpression of miR-1296
promoted the proliferation, tumorigenicity and cell cycle
progression of HCC cells. In agreement with these ob-
servations, upregulation of miR-1296 decreased the ex-
pression of p21Cip1, a cyclin-dependent kinase (CDK)
inhibitor, and increased the expression of the cell cycle
regulator cyclin D1 and Ki67. Moreover, we demonstrated
Figure 4 (See legend on next page.)
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Figure 4 FOXO1 is a direct target of miR-1269. A. Sequence alignment of miR-1269, miR-1269 mutant (miR-1269-mut), and putative FOXO1-
3’UTR. B. Real-time PCR analysis of miR-1269 and western blotting analysis of FOXO1 in 8 paired cancerous tissues (T) and their adjacent noncancerous
hepatic tissues (N). The quantification of western blotting bands is performed by OD value determined by Quantity One 4.6.2 software. C. Western
blotting analysis of expression levels of FOXO1 and phosphorylated FOXO1 in the indicated cells. α-Tubulin served as the loading control. D. The
FOXO1 luciferase reporter activity in the indicated cells transfected with miR-1269 mimic, or miR-1269-mut, miR-1269 inhibitor, or negative control.
E. Real-time PCR analysis of mRNA expression of p21, Cyclin D1 and Rb in the indicated HCC cell lines. F. Western blotting analysis of p21, cyclin D1,
Ki67, p-Rb, and Rb in the indicated HCC cells. α-Tubulin served as the loading control. Each bar represents the mean ± SD of three independent
experiments. * P < 0.05.
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targeting its 3’-UTR. Taken together, our results suggest
that upregulation of miR-1296 might play an important
role in promoting carcinogenesis and progression of HCC.
FOXO proteins are a subfamily of the forkhead tran-
scription factors [15]. FOXO1 is a potent transcriptional
activator that triggers the expression of a program of
genes involved in cell cycle arrest, apoptosis, DNA repair
and hypoxia responsiveness [16-19]. FOXO1 is also
known as a tumor suppressor and its deregulation has
been identified in various tumors [20]. Typically, inhib-
ition of FOXO1 in cancer is associated with the activation
of higher level kinases such as Akt and IKK (IκB kinase)
[15,17]. It is known that activated Akt leads to FOXO1
phosphorylation, resulting in FOXO1 translocating fromFigure 5 MiR-1269 promotes proliferation of HCC cells by suppressin
transfected with FOXO1-siRNA. α-Tubulin served as the loading control. B. T
by MTT assay. C. The quantification of crystal violet stained colonies formed by
of colony numbers of indicated cells treated with FOXO1-siRNA or NC, which d
the mean ± SD from three independent experiments. * P< 0.05.the nucleus to cytoplasm by binding with the 14-3-3
chaperone protein, and then subsequently undergoing
protein degradation [15,17]. The regulation of FOXO1 by
miRNAs has been reported elsewhere. For example, Anna
et al. found that FOXO1 is a bona fide target of miR-182
and mediated the function of miR-182 in promoting
clonal expansion of activated helper T lymphocytes [21].
Furthermore, three microRNAs, miR-27a, miR-96, and
miR-182, have all been found to directly target FOXO1
and regulate endogenous FOXO1 protein expression in
breast cancer cells, while suppression of these microRNAs
resulted in an increase in FOXO1 protein and a decrease
in cell growth [22]. It is also known that mir-223 regulates
cell proliferation through targeting and downregulating
FOXO1 [23], and upregulation of miR-370 promotesg FOXO1. A. Western blotting analysis of FOXO1 in the indicated cells
he effects of FOXO1 on miR-1269 mediated HCC proliferation analyzed
the indicated cells transfected with FOXO1-siRNA or NC. D. Quantification
etermined by anchorage-independent growth assay. Error bars represent
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expression FOXO1 [24]. In the present study, we found
that FOXO1 is a direct target of miR-1269, which could
downregulate its expression. These results supported the
viewpoint that, in addition to the regulation of FOXO1 by
phosphorylation, there are other regulatory mechanisms
that can modulate FOXO1 expression, i.e. epigenetic regu-
lation by miRNAs. Moreover, consistent with previous
studies, the regulation of FOXO1 by specific miRNAs is
essential in tumor development and progression.
CDK1 and CDK2, two cell cycle regulatory protein
kinases that play important roles in cell cycle transitions,
have been reported to phosphorylate FOXO1 and at-
tenuate its tumor suppressor function [25]. It has also
been reported that upregulation of the constitutively
active nuclear form of FOXO1 represses the activity of
CDK4, which is important for G1 cell cycle progression
controlled by cyclin D [26]. Moreover, previous studies
have shown that FOXO subfamily members play critical
roles in suppressing tumor growth by increasing the
expression level of the cell cycle inhibitor p21Cip1 and
p27Kip1, and decreasing the expression of the cell cycle
regulator cyclin D, consequently leading to G1/S cell
cycle arrest [24,27,28]. Consistent with this literature, we
found that ectopic miR-1269 inhibits the expression of
p21 Cip1, and induces the expression of cyclin D1.
Dalmasso, et al. found that transfection of enterocyte-
like Caco2-BBE cells with antisense of mature miR-1269
could decrease growth rate and trans-epithelial resistance
of the cells, indicating their shift toward colonocyte-like
HT29-Cl cells, which is one clone of human colonic can-
cer HT29 cells [29].
Conclusion
In conclusion, this study revealed that miR-1269 might
have potential function to determine human intestinal
epithelial cell fate. However, the function and regulation
of miR-1269 during HCC progression has not been
unfolded. Herein, for the first time we have revealed an
important link between miR-1269 and HCC progression.
We have shown that miR-1269 functions in regulating
cell growth, tumorigenicity, and cell cycle progression.
This work adds to the growing body of knowledge
concerning the essential role that miRNAs play in the
pathogenesis of cancer, and further suggests that miR-
1269 is an oncomiR and might represent a potential
therapeutic target for HCC.
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